Visceral leishmaniasis is a reemerging neglected tropical disease with limitations for its diagnosis, including low concentration of antibodies in the serum of asymptomatic patients and cross-reactions. In this context, this work proposes an electrochemical immunosensor for the diagnosis of visceral leishmaniasis in a more sensitive way that is capable of avoiding cross-reaction with Chagas disease (CD). Crude Leishmania infantum antigens tested in the enzyme-linked immunosorbent assay (ELISA) were methodologically standardized to best engage to the sensor. The antibodies anti-Trypanosoma cruzi and anti-Leishmania sp. Present in serum from patients with diverse types of CD or leishmaniasis were chosen. A screen-printed carbon electrode modified with gold nanoparticles was the best platform to guarantee effective adsorption of all antigens so that the epitope of specific recognition for leishmaniasis occurred efficiently and without cross-reaction with the evaluated CD. The current peaks reduced linearly after the recognition, and still were able to notice the discrimination between different kinds of diseases (digestive, cardiac, undetermined Chagas/acute and visceral chronic leishmaniasis). Comparative analyses with ELISA were performed with the same groups, and a low specificity (44%) was verified due to cross-reactions (high number of false positives) on ELISA tests, while the proposed immunosensor presented high selectivity and specificity (100%) without any false positives or false negatives for the serum samples from isolated patients with different types of CD and visceral leishmaniasis. Furthermore, the biosensor was stable for 5 days and presented a detection limit of 200 ng mL−1.
1 January 2022 in Journal of Stroke and Cerebrovascular Diseases
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has posed a major challenge to global health. The development of fast, accurate, and accessible diagnostic methods is essential in controlling the disease and mitigating its impacts. In this context, electrochemical biosensors present themselves as promising tools for the efficient monitoring of SARS-CoV-2 infection. We have developed a highly specific biosensor for the detection of anti-SARS-CoV-2 antibodies in patient sera. The use of the RBD-S region as an antigen, although purified to minimize cross-linking, poses a specific challenge. The structural similarity between SARS-CoV-2 and other respiratory viruses, as well as the complexity of the serum matrix, hinders robust analytical strategies to ensure diagnostic accuracy. This work presents a novel immunosensor for COVID-19 diagnosis using laser-induced graphene (LIG) electrodes subjected to electrochemical reduction with graphene (named rGraphene-LIG). In the present study, we chose an initial approach focused on demonstrating the concept and evaluating the feasibility of the rGraphene-LIG sensor for SARS-CoV-2 detection. The rGraphene-LIG electrodes presented a notable current increase for the redox probe in the aqueous solution of a mixture of 5 mmol L−1 potassium ferricyanide/ferrocyanide ([Fe(CN)6]3−/[Fe(CN)6]4−) in 0.1 mol L−1 KCl (pH set at 7.4). As a proof of concept, the rGraphene-LIG electrode was applied for antibody determination in real samples using cyclic voltammetry, and a limit of detection (LOD) of 0.032 μg L−1 was achieved. When determining antigens in commercial samples, we obtained an LOD of 560 ηg mL−1 and a limit of quantification of 1677 ηg mL−1. The results of the electrochemical experiments were in accordance with the surface roughness obtained from atomic force microscopy images. Based on these results, the rGraphene-LIG electrode is shown to be an excellent platform for immunoglobulin detection when present in individuals after antigenic exposure caused by SARS-CoV-2.
Visceral leishmaniasis is an endemic protozoonosis observed in over 60 countries, with over 500 000 new cases recorded annually. Although the diagnostic procedure of its symptomatic forms is well established, for asymptomatic patients, who represent about 85% of those infected, there is no consensus on the best method for its identification. Recent studies have presented molecular techniques as viable identification methods, with good sensitivity and specificity indices in asymptomatic individuals. Therefore, we aimed to use molecular methods to assess their effectiveness in identifying the presence of asymptomatic infection by Leishmania infantum (L. infantum) individuals from endemic regions of Brazil. Screening was performed by real-time polymerase chain reaction (qPCR) and confirmed by sequencing the cytochrome B gene. Of the 127 samples [from 608 blood donors who had participated in a previous study, of which 34 were positive by the enzyme-linked immunosorbent assay (ELISA) rK39] tested by qPCR, 31 (24.4%) were positive. In the sequencing of 10 qPCR-positive samples, five were identified as L. infantum. Complimentary samples of the ELISA rK39 and conventional PCR showed only reasonable and low agreement with qPCR, respectively. The qPCR confirmed the presence of infection in five of the 10 sequenced samples, ELISA confirmed three, and the conventional PCR confirmed none.
Knowing that ticks have bioactive molecules in their saliva which modulate hemostatic and immunomodulatory activities in humans, we carried out a systematic search for biomolecules present in tick saliva with great pharmacological potential. We evaluated studies published in the last ten years. Following the recommendations of the Prisma tool, primary and secondary studies of a systematic nature were selected, with no language or country restriction. Studies that included arthropods other than ticks and studies in which the use of saliva had no pharmacological application were excluded. For searches, we used the following databases: MEDLINE®/PubMed®, Web of Science, LILACS, EMBASE, Cochrane and SCOPUS. The methodological quality was performed using the tools available in Joanna Briggs, always with two or more independent evaluators. The generated data were tabulated and summarized through qualitative narrative analysis. The methodology selected 19 articles that met the eligibility criteria. The saliva of hard ticks, found in the Americas, is more promising when used in experimental studies with human cells. The elucidation of the biomolecules was possible, with evasin and serpine being the biomolecules with the most evident pharmacological potential for anti-inflammatory action. In the selected studies, we found only experimental studies, with no pre-clinical or clinical studies, making methodological qualification difficult; in some studies, with the biomolecule Evasin and Serpin, the need for elucidation of these biomolecules in question was suggested. Thus, we found evidence that the saliva of American hard ticks is the most studied for pharmacological applications of anti-inflammatory and immunomodulatory action.